JUNSHI BIO (688180.SH): The application for market approval of Teprotumumab Injection (subcutaneous injection) has been accepted.

JUNSHI BIO (688180.SH) announced that the company recently received an "Acceptance Notice" issued by the National Medical Products Administration, approving the market application for 12 indications of the company's product Toripalimab Injection (Subcutaneous Injection) (code: JS001sc) for tumor treatment. JS001sc is a subcutaneous injection formulation developed by the company based on its marketed product Toripalimab Injection (code: JS001). It is the first domestically produced anti-PD-1 monoclonal antibody subcutaneous injection formulation to enter the market application stage, providing convenience for patients. The 12 indications in the market application for JS001sc are all the indications approved for Toripalimab Injection in mainland China.